Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 73.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 516,469 shares of the biopharmaceutical company’s stock after selling 1,452,700 shares during the period. Handelsbanken Fonder AB owned about 0.41% of Halozyme Therapeutics worth $24,692,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $29,000. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the fourth quarter worth about $69,000. CWM LLC increased its holdings in Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,028 shares in the last quarter. Finally, Centaurus Financial Inc. bought a new position in Halozyme Therapeutics during the 3rd quarter worth approximately $127,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 0.6 %

Halozyme Therapeutics stock opened at $57.44 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $36.61 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $7.31 billion, a price-to-earnings ratio of 16.75, a PEG ratio of 0.44 and a beta of 1.25. The firm has a 50-day moving average price of $53.26 and a two-hundred day moving average price of $54.58.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 165.13% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.72 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research analyst reports. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Benchmark reiterated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $62.78.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.